Evidence map›Paper›PMID 32885413›Full record

ArticleClinical pharmacology and therapeutics2021

Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.

Flavia Storelli, Sarah Billington, Aditya R Kumar, Jashvant D Unadkat

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. OATP1A2 mediates AβFrontiers in pharmacology · 2024
    Article
  17. Review
  18. In vivo methods for imaging blood-brain barrier function and dysfunction.European journal of nuclear medicine and molecular imaging · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Flavia StorelliDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Sarah BillingtonDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Aditya R KumarDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Jashvant D UnadkatDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
University of Washington · US

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
Understanding Fetal Exposure to Cannabinoids Through In Vitro and In Vivo StudiesP01DA032507 · NIDA · UNIVERSITY OF WASHINGTON · PI UNADKAT, JASHVANT D · 2013 to 2023
$12.4M
P-glycoprotein and Alzheimer's DiseaseR33AG031485 · NIA · UNIVERSITY OF WASHINGTON · PI UNADKAT, JASHVANT D · 2008 to 2010
$950k
NIA NIH HHS P50 AG005136NIA NIH HHS R33 AG031485NIA NIH HHS U01 AG006781NIDA NIH HHS P01 DA032507
6 · The paper itself

Abstract

The human blood-brain barrier (BBB) transporter P-gp can efflux amyloid-β (Aβ) out of the central nervous system (CNS). Aβ is thought to be the causative agent for Alzheimer's disease (AD). Using positron emission tomography imaging, we have shown that BBB P-gp activity is reduced in AD, as quantified by the in vivo brain distribution of the P-gp probe [

Indexed as

ProteomicsAdultAgedAged, 80 and overAge FactorsAlzheimer DiseaseAmyloid beta-PeptidesATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2Biological TransportBlood-Brain BarrierCase-Control StudiesEquilibrative Nucleoside Transporter 1FemaleGray MatterHumansABCG2 protein, humanAmyloid beta-PeptidesATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2Equilibrative Nucleoside Transporter 1Low Density Lipoprotein Receptor-Related Protein-1LRP1 protein, humanNeoplasm ProteinsOrganic Anion TransportersSLC29A1 protein, humanSLCO2B1 protein, humanVerapamil

Identifiers

PMID32885413
PMCPMC7902298
OpenAlexW3083082591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.